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Abstract
Prompt removal of apoptotic cells by phagocytes is important for maintaining tissue homeostasis.
The molecular and cellular events that underpin apoptotic cell recognition and uptake, and the
subsequent biological responses are increasingly better defined. The detection and disposal of
apoptotic cells generally promote an anti-inflammatory response at the tissue level, as well as
immunological tolerance. Consequently, defects in apoptotic cell clearance have been linked with
a variety of inflammatory diseases and autoimmunity. Conversely, under certain conditions such
as killing tumour cells by specific cell death inducers, the recognition of apoptotic tumour cells
can promote an immunogenic response and anti-tumour immunity. Here, we review the current
understanding of the complex process of apoptotic cell clearance in physiology and pathology, and
discuss how this knowledge could be harnessed for new therapeutic strategies.
Apoptosis or programmed cell death (in contrast to necrosis – see Box 1) occurs throughout
life in essentially all tissues as part of normal development, homeostasis, and pathogenic
processes. Despite the constant turnover of cells through apoptosis, apoptotic cells are rarely
seen under physiological conditions, even in tissues with high rates of apoptosis. For
example, about 80% of developing thymocytes eventually undergo apoptosis, yet free
apoptotic cells are rarely observed in the thymus. This suggests that in the steady state, the
rate of apoptotic cell removal is high, and this seems to be a pre-requisite for the continued
clearance of the estimated one million cells that undergo apoptosis in various tissues every
second in adult humans1. Dying cells are removed either by tissue-resident professional
phagocytes (such as macrophages and immature dendritic cells (DCs)) or by neighbouring
non-professional phagocytes.
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Box 1
Immune recognition of membrane-permeabilized (necrotic) cells
The plasma membrane can be become permeable in response to physical and chemical
insult (primary necrosis) or when uncleared apoptotic cells begin to lose membrane
integrity (secondary necrosis). Membrane lysis can also occur through an active
mechanism, when tumour necrosis factor receptor 1 (TNFR1) signalling is activated by
TNF along with caspase 8 inhibition, a process known as necroptosis or programmed
necrosis. Initiation of necroptosis depends on the activation of receptor-interacting
protein 1 (RIP1) and RIP3 kinases148. Activation of caspase 1 by pathological stimuli
such as microbial infection can also trigger membrane permeabilization by a form of cell
death known as pyroptosis149. Furthermore, neutrophils and eosinophils can undergo
another form of programmed cell death with release of extracellular traps (termed NETs)
in response to pathogens and in response to sterile inflammatory mediators150,151 with
potential antimicrobial but pro-inflammatory consequences.
A key feature of membrane lysis is the display and/or release of intracellular molecules
that are otherwise hidden from the extracellular environment. Exposure of certain
intracellular molecules can trigger inflammation and signal ‘danger’152 to the immune
system. Such endogenous molecules (also known as damage-associated molecular
patterns (DAMPs)) include: high-mobility group box 1 (HMGB1), SAP130, heat shock
protein 90 (HSP90), DNA, uric acid and monosodium urate crystals, and IL-33. These
endogenous molecules can be recognized variably by Toll-like receptors (TLRs), the C-
type lectin Mincle, receptor for advanced glycation end-products (RAGE) and
ST2153,154. Interestingly, interaction of HMGB1 and HSP90 with CD24 on responding
cells may dampen their immunostimulatory properties to fine-tune the immune
response155. Membrane permeabilized cells may also expose molecules that are similar
to intact apoptotic cells (such as PtdSer), so the recognition mechanisms that are used to
mediate apoptotic and necrotic cell removal may overlap. Notably, in addition to direct
recognition by phagocytes, many serum opsonins have been found to preferentially aid
the clearance of membrane permeabilized cells156. Furthermore, selective detection of
membrane-damaged cells by receptors such as Clec9A may have an important role in
regulating antigen cross-presentation by CD8α+ DCs157,158.
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Box 1.
Handling membrane permeabilizwd (necrotic) cells
In contrast to phagocytosis of bacteria and other ‘danger-associated’ particles, clearance of
apoptotic cells is immunologically quiescent under physiological circumstances, and does
not involve influx of inflammatory cells into the healthy tissues or a breakdown in immune
tolerance against self-antigens. Recently, there has been a significant accumulation of
knowledge on the molecular details of the apoptotic cell clearance process and on its
functional relevance to disease. Such knowledge has created an exciting stage to further
explore the potential therapeutic benefits of targeting the apoptotic cell clearance machinery
in a variety of diseases ranging from autoimmunity to cancer.
In this Review, we introduce the key molecular features of the apoptotic cell clearance
process, and then discuss the relevance of apoptotic cell clearance process to infection,
inflammatory disease, autoimmunity, transplantation, and cancer. Finally, we examine how
targeting this clearance machinery could provide therapeutic benefits.
Molecular steps in apoptotic cell removal
Prior to their recognition by phagocytes, apoptotic cells undergo a number of distinct
morphologic changes. These changes may in turn facilitate an apoptotic cell to be
recognized and cleared. An intriguing issue with respect to morphologic changes during
apoptosis is whether phagocytes engulf the apoptotic cells ‘in whole’ or in smaller ‘bite-
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size’ fragments. There is evidence for both. In most instances, the professional phagocytes
appear to phagocytose the targets in their entirety – this is particularly apparent in the case
of macrophages or DCs that engulf apoptotic thymocytes or neutrophils2,3. Even fibroblasts
and epithelial cells appear to engulf similarly sized dying brethren in tissues and ex vivo4,5.
However, there are other instances where a phagocyte simply cannot engulf the dying target
in its entirety, possibly due to sheer size difference between the phagocyte and the target.
For example, in inflamed adipose tissue, dying adipocytes appear to be engulfed by multiple
macrophages that form ‘crown-like structures’ around a single adipocyte and ingest smaller
fragments of the dying cell6. This has also been observed during clearance of dying cells by
fibroblasts in the absence of macrophages2. In fact, the formation of plasma membrane blebs
(a common morphologic feature of apoptosis) is required for the generation of smaller
apoptotic cell fragments (known as apoptotic bodies). In multiple cell types, activation of
Rho-associated kinase ROCK I by caspase 3-mediated cleavage enhances phosphorylation
of myosin light chain, which in turn promotes actomyosin contraction, membrane blebbing
and the formation of apoptotic bodies7,8 (Figure 1). Although some of the extensive
membrane blebbing that has been observed in cultured cancer cells following apoptosis
induction may be due to lack of neighbouring phagocytes or represent late stages of cell
death, apoptotic blebs have been observed on apoptotic cells in native tissues9. What
fraction of the apoptotic cells that might be cleared through the formation of such ‘bite-size’
fragments in vivo, and whether the ‘rest’ of the corpse gets ingested as a larger target
remains to be determined. Thus, in different tissues, depending on the relative sizes of the
phagocyte and the target being ingested, the corpses may be taken either in whole, or in
smaller fragments. However, it is notable that in the case of substantial and excessive
apoptosis, uncleared apoptotic cells and fragments may lose their membrane integrity
(undergoing secondary necrosis) and are likely removed via other phagocytic mechanisms
(Box 1).
Another interesting question with respect to morphology of dying cells is how apoptotic
cells that are part of an epithelial sheet, such as epithelial cells in the gut or airways, can be
removed, and how the integrity of the epithelial barrier is maintained. This is not a trivial
issue when one considers that in the gut of an adult human, an epithelial surface area
roughly equivalent to a tennis court is replaced every 4–7 days. For cells held by attachment
to the extracellular matrix, to neighbouring cells or to synthetic surfaces, detachment from
the surrounding environment can be induced by caspase-mediated cleavage of components
regulating focal adhesion10,11 and adherens junction components, such as E-cadherin, P-
cadherin and β-catenin12,13. Viable neighbouring cells might replace such ‘loosened’ dying
epithelial cells while the corpse is being removed. Alternatively, cell extrusion into the
organ lumen or another tissue space14 might allow for subsequent apoptotic cell removal by
luminal phagocytes such as alveolar macrophages. It remains to be determined whether
phagocytosis of apoptotic epithelial cells in different tissues involves mainly cell extrusion
or other mechanisms.
Recruiting the ‘right’ phagocyte to prevent inflammation
It is now becoming increasingly clear that apoptotic cells at the earliest stages of death
‘advertise’ their presence to facilitate their own removal by recruiting phagocytes. The latter
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are usually motile tissue-resident phagocytes, although in model systems recruitment
directly from the circulation can also occur15. Apoptotic cells can attract phagocytes through
the release of chemotactic factors, which are known as ‘find-me’ signals. These find-me
signals can be soluble, or signal via submicron membrane vesicles (Figure 1 and Table 1).
Nucleotides such as ATP and UTP have been identified as key mediators of phagocyte
recruitment towards apoptotic cells in vitro and in vivo. This process requires caspase-
mediated activation of pannexin 1 (PANX1) channels to release nucleotides from apoptotic
cells16 and subsequent nucleotide detection by purinergic receptors (such as P2Y2 and
possibility others) on monocytes and macrophages15. It is notable that nucleotides like ATP
can also be secreted from cells via other active mechanisms (for example through
exocytosis, autophagy-dependent and independent processes) and passive mechanisms (for
example through membrane permeabilization). The release of ATP into the extracellular
milieu can further modulate inflammation in a complex manner depending on its
concentration, and how rapidly it is being degraded into immunosuppressive adenosine
(discussed extensively in a recent review17). Lysophosphatidylcholine and sphingosine 1-
phosphate have also been linked with monocyte recruitment to the proximity of apoptotic
cells, but their in vivo relevance remains to be further defined18,19.
Small membrane vesicles released from apoptotic germinal centre B cells have been
reported to enhance monocyte migration20. Consistent with this observation, certain
molecules including intercellular adhesion molecule 3 (ICAM3) and a proteolytically
processed form of CX3C-chemokine ligand 1 (CX3CL1; also known as fractalkine) were
found to associate with apoptotic cell-derived microparticles and promote macrophage
chemotaxis21,22. It is worth noting that phagocyte recruitment via microparticle-associated
molecules could be a mechanism restricted to certain cell types that generate microparticles
during apoptosis (for example, Burkitt lymphoma cells) and this area remains to be better
explored.
In addition to attracting certain phagocytes, apoptotic cells are thought to release factors,
referred to as ‘keep-out’ signals, to exclude inflammatory cells such as neutrophils (Table
1). Lactoferrin, a multifunctional glycoprotein, is the only keep-out signal discovered to
date23, and its expression is upregulated in various cell types following induction of
apoptosis. Lactoferrin is released by apoptotic cells and purified lactoferrin can inhibit
neutrophil chemotaxis in vitro and in vivo, possibly by dampening neutrophil activation.
Importantly, although it has also been shown to limit eosinophil recruitment24, lactoferrin
had no effect on monocyte or macrophage migration towards the chemoattractant
complement component C5a, demonstrating selectivity in inhibiting neutrophil and
eosinophil migration23,24. It is important to note that there is limited information regarding
the repertoire of find-me and keep-out signals released by different cell types during
apoptosis. In fact, whether various find-me signals can function synergistically or additively
to recruit phagocytes is not well defined. Nevertheless, it is intriguing to consider the
possibility that apoptotic cells can release a unique combination of factors to control the
recruitment of appropriate phagocytes for cell clearance and limit inflammation.
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Specific recognition of apoptotic cells by phagocytes
Phagocytes identify apoptotic cells among healthy viable cells based on a unique
combination of signals on the surface of apoptotic cells (Figure 1 and Table 1). Increased
surface exposure of the inner-membrane lipid phosphatidylserine (PtdSer) is a common (but
not exclusive) feature of apoptotic cells and functions as a key ‘eat-me’ signal to trigger
phagocytic uptake25. The precise machinery that controls surface exposure of PtdSer during
apoptosis is still being defined. However, recent studies suggest that both the calcium-
dependent and calcium-independent activities of phospholipid scramblase disrupt the
aminophospholipid asymmetry of the plasma membrane and promote PtdSer exposure
during apoptosis26–28. It is worth noting that a substantial amount of PtdSer exposure is
necessary for detection by phagocytes29.
Several PtdSer recognition mechanisms have been identified recently (Table 1). PtdSer can
be detected directly via membrane receptors, such as brain-specific angiogenesis inhibitor 1
(BAI1)30, stabilin-231,32 and members of T cell immunoglobulin mucin domain (TIM)
protein family (including TIM1, TIM3 and TIM4)33–35. Recognition of PtdSer by the seven
span transmembrane protein BAI1 can signal through the evolutionarily conserved ELMO1–
DOCK180–RAC complex to facilitate cytoskeletal rearrangement for engulfment (Figure
1)30. Similarly, stabilin-2 may interact with the adaptor protein GULP and thymosin β4 to
initiate apoptotic cell uptake following PtdSer binding36,37. TIM4 seems to function
primarily as a tethering protein for PtdSer and to signal through its associated proteins to
promote engulfment38. In addition to these bona fide PtdSer receptors, bridging molecules,
including milk fat globule-EGF factor 8 (MFG-E8), Protein S and Gas6, can bind PtdSer
and are in turn recognized by their cell surface receptors on phagocytes, such as the integrin
αVβ3 and the Tryo3–Axl–Mer (TAM) family of receptors39–41 (Table 1). It is intriguing that
multiple PtdSer recognition mechanisms have been described for apoptotic cell clearance. It
remains to be defined in mammals whether a particular mode of PtdSer recognition may be
required only under specific conditions (for example, tissue development, homeostatic cell
turnover, and inflammation) or whether these multiple mechanisms provide a degree of
redundancy. Nevertheless, the growing availability of mice deficient in PtdSer recognition
receptors and bridging molecules and in vivo models to assess the functional consequences
of apoptotic cell removal are expected to help understand the need for such array of PtdSer
sensing pathways.
In addition to PtdSer, surface exposure of calreticulin (CRT) on apoptotic cells may function
as another eat-me signal. Induction of cancer cells to undergo apoptosis through mechanisms
that also promote endoplasmic reticulum (ER) stress (such as anthracyclin treatment and
photodynamic therapy) seems to result in rapid translocation of CRT from the ER to the
plasma membrane42–45. Exposed CRT can subsequently be detected by CD91 (which is also
known as low density lipoprotein (LDL)-receptor related protein) on phagocytes to stimulate
engulfment42 (Figure 1). Notably, CRT exposure seems to trigger an immunogenic response
against apoptotic cell-derived antigens, rather than inducing immunological tolerance43–45.
It is apparent that displaying certain eat-me signals alone may not be sufficient to trigger
apoptotic cell engulfment42,46. For example, constitutive PtdSer exposure on viable
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lymphoma cells that express a mutant form of the scramblase TMEM16F (also known as
Anoctamin 6) did not promote their uptake by peritoneal macrophages or CD8+ splenic
DCs46. These observations support the idea that healthy viable cells, which can also expose
PtdSer under physiological circumstances, might actively suppress phagocytic uptake by
displaying ‘don’t eat-me’ signals such as CD31, CD47 and CD46 (Table 1). Engagement of
CD47 (also known as integrin-associated protein) on viable cells with signal regulatory
protein-α (SIRPα) on the macrophages can negatively regulate engulfment42,47,48, whereas
redistribution or loss of CD47 during apoptosis may promote cell clearance42. Furthermore,
loss of complement regulatory protein CD46 on various cell types during apoptosis can lead
to complement opsonization49, a process that may aid phagocyte recognition. In addition, it
remains to be fully investigated whether the exact configuration of PtdSer on the cell surface
of live and apoptotic cells mediates differing signals. Collectively, exposure of a sufficient
amount of eat-me signals and loss of don’t eat-me signals on the surface of apoptotic cells
are necessary to trigger their removal by phagocytes.
Translating the final message
As cell death can arise under a variety of physiological and pathological conditions,
including tissue development, homeostatic cell turnover, tissue injury, inflammation,
tumorigenesis and infection, apoptotic cells might carry important and complex information
for the regulation of the downstream immune response in a context-dependent manner. So,
how do apoptotic cells convey such a diverse array of immunological information?
Answering this question requires the consideration of all potential variables that occur with
cell death.
The first parameter to consider is the quality of apoptotic cells, which determines what type
of eat-me signals are being exposed to the immune system. Factors that can determine the
quality of apoptotic cells include cell type, cause of cell death, and activation status of the
dying cells. As discussed above, induction of apoptosis via certain anti-cancer drugs can
render apoptotic tumour cells pro-immunogenic, whereas apoptosis during developmental or
‘homeostatic’ processes is largely anti-inflammatory and immunologically silent.
In addition, the quantity of apoptotic cells may determine the magnitude of signals.
Although cell death in steady state tissues is easily and efficiently handled without inducing
an immune response, large numbers of apoptotic cells such as those observed during
infection or induced by anti-tumour therapies may overwhelm the engulfment capacity
locally, and the uncleared cells or other components of these dying cells could induce a pro-
immunogenic response. Another key parameter to consider is the apoptotic cell
microenvironment, which determines what type of phagocyte is available to mediate
clearance and regulate the subsequence immune response. This is particularly relevant for
immune-privileged tissues such as the brain, eye and testes.
Finally, the timing of cell death and duration of apoptotic cell-derived signals may also
contribute to the final immunological outcome. Thus, depending on the specific
experimental condition, apoptotic cells may promote immunity or tolerance. It should also
be noted that in certain instances, apoptotic cells can have a beneficial effect in tissue
development and repair, as observed in myoblast fusion9 and wound healing50. A better
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characterization of the parameters of cell death and apoptotic cell clearance that influence
immune activation might help us to understand certain disease states and to develop
apoptotic cell-based or cell clearance-targeting therapeutic approaches.
Targeting apoptotic cell clearance for therapy
Apoptotic cells are rarely detected under physiological conditions, and the presence of
uncleared apoptotic cells has been linked to several different diseases that involve inflection,
inflammation, autoimmunity and cancer. In this section, we review the evidence that links
defective cell clearance with the initiation and progression of pathology and discuss
potential therapeutic implications (Figure 2 and Box 2).
Box 2
Endogenous controllers of apoptotic cell clearance
During the spontaneous resolution of an episode of inflammation, locally produced
molecules modulate apoptotic cell clearance. These include the specialised pro-resolving
lipid mediators lipoxins (which are generated from arachidonic acid), resolvins and
protectins (which are generated from omega-3 fatty acids)159. Although these different
classes of pro-resolving lipids are distinct in both their production and biological effects,
they all reduce neutrophil recruitment and enhance clearance of apoptotic cells.
Apoptotic neutrophils enhance the production of pro-resolving lipid mediators by
macrophages during their engulfment160. The benefits of these molecules have been
shown in animal models of inflammation including asthma161, lung injury62,162 and
colitis163. Furthermore, emerging evidence has demonstrated that they also contribute to
anti-microbial defence during bacterial infection164. There is also evidence that pro-
resolving lipid production may be deficient in human inflammatory disease165 although
this is an area requiring further study. Despite the locally acting and short-lived nature of
these lipid mediators, structural analogues with longer half-lives have been developed,
and pro-resolving lipid mediators are undergoing early clinical trials in humans
(ClinicalTrials.gov; NCT01675570 and NCT01639846).
Lysophosphatidylserine (lysoPS), a lipid exposed on apoptotic cells (particularly
neutrophils) in a NADPH oxidase-dependent manner has been shown to enhance
macrophage engulfment166,167. This may partly explain why patients with chronic
granulomatous disease (CGD) that lack a functional NADPH oxidase have defects in
apoptotic cell clearance and a hyper-inflammatory phenotype with a propensity for
autoimmune disease168.
Tissue resident macrophages express 12/15-lipoxygenase that can generate oxidised
phosphatidylethanolamine (oxPE) on their cell membranes169. oxPE has been shown to
bind soluble apoptotic cell-bridging molecule MFG-E8 and thus prevent uptake of
apoptotic cells by recruited inflammatory monocytes169. This binding and sequestering of
MFG-E8 by oxPE does not inhibit the engulfment of apoptotic cells by tissue-resident
macrophages, which predominantly recognize apoptotic cells through the PtdSer receptor
T cell immunoglobulin domain and mucin domain protein 4 (TIM4). Lack of 12/15-
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lipoxygenase results in apoptotic cell clearance by inflammatory monocytes or
macrophages, with the subsequent presentation of apoptotic cell-derived intracellular
antigens and development of autoimmunity with glomerulonephritis169. Whether defects
in lysoPS production or in the control of 12/15-lipoxygenase activity are defective in
human disease is currently unknown, but the targeting and mimicking of endogenous
controllers of apoptotic cell clearance is an attractive therapeutic avenue.
Box 2.
Apoptotic cells as a potential therapeutic intervention
Infection
In response to an acute episode of infection or tissue injury, tissue-resident cells (both
immune and parenchymal) detect pathogen-associated molecular patterns (PAMPs),
including bacterial endotoxin and viral nucleic acids, as well as damage-associated
molecular patterns (DAMPs), the latter being mainly intracellular proteins and substrates
released upon cell death51. As a consequence, leukocytes are recruited to the site of
inflammation, with innate immune cells such as neutrophils often being the first cells to
appear and accumulation of mononuclear cells and macrophages occurring at a later stage52.
This initial robust immune response is a beneficial one, designed to contain and destroy
invading pathogens and enhance repair of tissue function53,54. Once the initial threat has
been eliminated, leukocyte recruitment ceases and the already recruited cells are disposed of
to restore homeostasis. Although recruited neutrophils can be cleared through transepithelial
migration into the airway lumen in the context of lung inflammation55, or through migration
via lymphatic vessels56, it appears that a main clearance route is by local neutrophil
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apoptosis and subsequent phagocytic clearance57,58. Both tissue resident and recruited
macrophages, as well as local epithelial cells, can ingest apoptotic leukocytes59.
Following neutrophil recruitment into infected tissue, exposure to bacterial-derived products
initially enhances the lifespan of neutrophils. However, the phagocytosis of pathogens, such
as Escherichia coli or Staphylococcus aureus, promotes a form of apoptotic cell death of
neutrophils that is termed phagocytosis-induced cell death (PICD)60 (Figure 2). This
response is believed to be primarily protective for the host, allowing a second round of
destruction of pathogens that might remain within the engulfed apoptotic neutrophils.
Incidentally, pharmacological acceleration of neutrophil apoptosis is protective in
pneumococcal meningitis with accelerated recovery and reduced brain haemorrhage61. The
production of small, locally acting, endogenous lipid-derived autacoids that promote the
removal of apoptotic cells (termed pro-resolving lipids) are also involved in limiting
infection-associated inflammation (Box 2). The pro-resolving lipid Resolvin E1 has recently
been demonstrated to promote PICD and thereby enhance the resolution of bacterial
infection in mice62.
However, pathogens can also utilise engulfment machinery for their benefit: phagocytosis of
apoptotic neutrophils infected with the intracellular pathogen Chlamydia pneumoniae has
been shown to result in the subsequent infection of macrophages63. This ‘Trojan horse’
strategy adopted by C. pneumoniae increases its virulence and replication when compared to
direct infection of macrophages. Moreover, bacteria can enter a cell using cytoplasmic
proteins that are also involved in engulfment of apoptotic cells; for example, IpgB1 of
Shigella flexneri induces membrane ruffling via ELMO1 activation, promoting bacterial
invasion of epithelial cells64. Therefore, enhancing the activity of the engulfment machinery
or neutrophil apoptosis in specific infections to mediate pathogen clearance is an exciting
possibility, but more investigation is needed.
Lung inflammation
Impaired or defective clearance of dying neutrophils during inflammation can lead to a
prolonged inflammatory response. Although the best evidence for this has come from animal
studies, such a phenomenon has also been observed in human disease, including chronic
obstructive pulmonary disease (COPD)65, pulmonary fibrosis66 and cystic fibrosis67. The
mechanism underlying impaired phagocytosis in inflammation involves, in part, the
production of reactive oxygen species (ROS) by neutrophils (Figure 2). ROS activate the
GTPase RhoA (a negative regulator of efferocytosis; a term that has also been used to
describe the phagocytic clearance of apoptotic cells) in surrounding phagocytes, thereby
reducing apoptotic cell engulfment by neighbouring cells68–70. Interestingly, antioxidants
such as the thiol compound N-acetylcysteine (NAC) promote clearance of apoptotic cells by
macrophages during lipopolysaccharide (LPS)-mediated lung inflammation in mice by
inhibiting both ROS production and RhoA activity and NAC can also enhance transforming
growth factor-β (TGFβ) production71. However, anti-oxidant therapy in humans with acute
lung injury and acute respiratory distress syndrome has thus far provided no convincing
evidence of efficacy72. Perhaps the drugs fail to reach the relevant phagocytes, or such
therapies need to be targeted to specific subgroups of patients with this disorder.
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Although alveolar macrophages from adult patients with asthma of mild to moderate
severity have normal phagocytic capacity, those from patients with severe asthma are
defective in clearing apoptotic cells73. Similarly, alveolar macrophages from children with
poorly controlled asthma have defective phagocytosis74. The molecular events causing
defective phagocytosis in patients with severe asthma are not yet understood, but it is
relevant to note that corticosteroids, the mainstay of treatment in asthma, not only induce
eosinophil apoptosis75 but also enhance eosinophil engulfment by monocyte-derived
macrophages in vitro76. This corticosteroid-induced enhanced clearance depends on the
binding of protein S to apoptotic cells and the upregulation of Mer tyrosine kinase (a
member of the TAM family) on the surface of macrophages77 (Figure 2). Furthermore,
enhanced clearance of apoptotic eosinophils by macrophages has been observed in asthmatic
humans after steroid therapy78. Steroid treatment appears less effective in neutrophil-
dominated lung inflammatory disorders and the ability of steroids to induce neutrophil
apoptosis seems to be context dependent79,80. In addition to alveolar macrophages and lung-
associated DCs, airway epithelial cells have been recently reported to engulf neighbouring
apoptotic cells, and a defect in this process increases the production of pro-inflammatory
mediators and exacerbates airway inflammation5. With this increased evidence of defective
apoptotic cell clearance in lung inflammatory diseases, and the mechanisms behind the
therapeutic benefits of commonly used anti-inflammatory medications such as
corticosteroids, it is hoped that novel approaches for targeting inflammatory diseases (within
the lung and in other tissues) are on the horizon.
Atherosclerosis
Atherosclerosis is one of the leading causes of death in western societies, and its
pathogenesis involves chronic inflammation of the vascular wall, predominantly as a result
of the accumulation of mononuclear immune cells81. Monocytes and macrophages have a
crucial role in the initiation and progression of atherosclerosis. Although there are resident
macrophages in the arterial wall, recruitment of Ly6C+ inflammatory monocytes and Ly6C−
‘patrolling’ monocytes, and their differentiation into macrophages and DCs are thought to
critically influence atherosclerosis82. After taking up various oxidized lipids in the intima,
lipid-laden macrophages undergo apoptosis and can be engulfed by surrounding
macrophages82. In the early stages of atherosclerosis, apoptosis in the vascular walls seems
to be counterbalanced by rapid and efficient engulfment82. However, in mature
atherosclerotic lesions (known as plaques), there is reduced clearance of apoptotic cells and
progression to secondary necrosis (Box 1), which coincides with plaque lesion expansion
and an increased risk of rupture83. Such plaque rupture leads directly to acute coronary
syndromes and stroke in humans.
This reduction in apoptotic cell clearance observed in mature plaques appears central to the
pathological process of plaque progression84, as defects in the phagocytic components such
as Mer, MFG-E8, or the complement component C1q results in the accumulation of
apoptotic debris within plaques and accelerates atherosclerosis85–88. Conversely, induction
of apoptosis within plaques by a physiological stimulus (for example through TNF-related
apoptosis-inducing ligand (TRAIL)), has been shown to be beneficial and
atheroprotective89, which is thought to be due to increased anti-inflammatory signalling
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within this microenvironment. Therefore, defective macrophage engulfment, and in turn, a
more pro-inflammatory state, seems to drive accelerated atherosclerosis. Importantly,
healthy phagocytes release anti-inflammatory cytokines that dampen inflammation
following apoptotic cell clearance82 and may help control atherosclerosis progression.
But, why do human macrophages in situ lose the ability to rapidly clear dead cells?
Although the reasons for this are incompletely understood and likely multifactorial, several
possible mechanisms have been suggested. Oxidised lipoproteins, which are present in
plaques in vivo, inhibit efferocytosis in vitro by binding to CD1490. In addition, the activity
of Rho kinase is reported to be increased in atherosclerotic lesions91. Interestingly, the
widely used HMG-CoA reductase inhibitors (also known as statins), which are principally
used as cholesterol lowering agents in atherosclerosis and vascular disease, have long been
thought to have additional anti-inflammatory effects partly due to enhancement of the
phagocytic activity of macrophages92. The mechanism underlying enhanced phagocytosis
induced by statins involves RhoA inhibition93 (Figure 2). RhoA activates the Rho-associated
protein kinases (ROCKs), which have an inhibitory effect on engulfment. Interestingly, the
ROCK inhibitor Fasudil inhibits both the early development and late progression of
atherosclerosis in mice94, although these beneficial effects have not yet been linked to
enhanced efferocytosis. Statins and ROCK inhibitors also display anti-inflammatory effects
in other non-vascular pre-clinical models of inflammation including acute lung injury95,
bleomycin-induced pulmonary fibrosis96 and inflammatory arthritis97, although a direct link
between these effects and phagocytosis of dying cells is not yet established.
Uptake of apoB-containing lipoproteins by macrophages that accumulate within the vascular
walls, which leads to foam cell formation, is a key early event in atherosclerosis98,99.
Improved cholesterol efflux from foam cells can revert this stage of atherosclerosis leading
to macrophage egress and a reduction in lesion size100. It was previously shown that when
macrophages engage apoptotic cells (but not necrotic cells), cholesterol efflux is stimulated
from the engulfing macrophages101. The enhanced cholesterol efflux by macrophages
occurs through upregulation of mRNA and protein for the cholesterol transporter
ABCA1101. ABCA1 is an important molecule in macrophage cholesterol efflux and
transports free cholesterol from within the cells to lipid-poor apoA1 that is then modified in
the plasma for transport to the liver and excretion102,103. Loss of ABCA1 promotes
atherogenesis, whereas overexpression of ABCA1 reverses the disease104,105. Recent reports
suggest that ABCA1 upregulation and signalling downstream of ABCA1 (after binding to
apoA1) can also dampen macrophage inflammatory responses81,106,107. Thus, ‘foamy’
macrophages undergoing necrosis in late-stage lesions might fail to upregulate ABCA1
expression, thereby preventing the cholesterol efflux and ABCA1-mediated immuno-
suppressive effects81,106,107. The precise phagocytic receptor(s), which upon apoptotic cell
recognition would induce the upregulation of ABCA1, and in turn the cholesterol efflux
from the phagocytes are not yet defined.
Other downstream modulators of the phagocyte response to ingested apoptotic cells include
activation of the nuclear receptors liver X receptors (LXRs) and peroxisome proliferator-
activated receptors (PPARs), which can act as positive regulators of engulfment by
upregulating Mer expression108 (Figure 2). LXR activation by synthetic agonists has been
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demonstrated to have beneficial effects in animal models of atherosclerosis109. In addition,
activators of PPARs have already been approved for clinical use in the treatment of diabetes,
as they have been shown to enhance murine macrophage efferocytosis110 and reduce
progression of atherosclerosis in humans in a glucose homeostasis-independent manner111.
Therefore such treatments may have additional beneficial effects via promotion of apoptotic
cell clearance.
Autoimmunity
Systemic lupus erythematosus (SLE) is a chronic systemic autoimmune disorder with a
variable clinical presentation commonly affecting skin, lungs, kidneys and the central
nervous system. It is characterised by the presence of auto-antibodies that are specific for
nuclear components and, frequently, with the detection of DNA and nucleosomes in the
circulation112. In patients with SLE, there is increased spontaneous appearance of apoptotic
cells within lymph nodes and blood, and accumulation of apoptotic cells within the skin
following UV exposure113,114. This increase in apoptotic cells observed in SLE is thought to
reflect an impaired ability of SLE phagocytes to engulf dead cells, rather than an intrinsic
alteration in the apoptotic programme115. In mice lacking MFG-E8, an accumulation of
apoptotic lymphocytes within lymph nodes and development of an SLE-like disease that
involves autoantibody formation, splenomegaly and glomerulonephritis are observed116.
Genetic polymorphisms and aberrant splicing of MFG-E8 have been reported in a small
subsets of patients with SLE, suggesting that this pathway of apoptotic cell clearance might
be dysregulated in a subset of human SLE patients117,118. Such impaired clearance of
apoptotic cells eventually leads to secondary necrosis, which allows intracellular antigens,
normally compartmentalised within an apoptotic cell, to gain access to the extracellular
environment. This presumably increases the risk of such antigens being recognised as non-
self with production of auto-antibodies and consequent autoimmunity. Complement proteins
also have a key role in apoptotic cell clearance and development of autoimmunity, and
deficiencies in complement components, especially C1q, are highly associated with
SLE119,120.
It is notable that not all defects in apoptotic cell clearance seem to result in autoimmunity:
the absence of CD14 or mannose binding lectin (MBL) in mice leads to defective apoptotic
cell engulfment and their accumulation in tissues, but does not have any pro-inflammatory
or autoimmune consequences121,122. Whether apoptotic cells in these deficient mice can still
provide a downstream immunomodulatory signal to prevent autoimmunity, despite not being
engulfed, requires further investigation. If apoptotic cell engagement alone by a phagocyte
can be beneficial in ameliorating autoimmunity, harnessing those features could offer a
therapeutic modality even in the context of continued defective apoptotic cell clearance.
Rheumatoid arthritis is a chronic systemic inflammatory disease associated with progressive
joint destruction. It is a systemic autoimmune disease with most individuals having
circulating autoantibodies against citrullinated peptides. Although there is little direct
evidence that human inflammatory arthritis is caused by defects in cell clearance123,124,
extracellular debris present at sites of inflammation such as oxidised lipids and intracellular
components including HMGB1, histone H3 and histone H4 are negative regulators of
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efferocytosis125. Histone H3 binds to macrophages, most likely by the binding to αvβ5
integrins, which decreases uptake in vitro and in vivo. This reduced engulfment by histones
can be reversed by administration of activated protein C which causes degradation of
histones125 (Figure 2). Similarly, HMGB1 reduces phagocytosis both by the binding to and
masking of PtdSer on apoptotic neutrophils as well as binding the αvβ3 integrin on
phagocytes126 (Figure 2). Furthermore, increasing the levels of TAM receptor-agonists
protein S and Gas-6127, LXR agonists128 and PPARγ activators129 have shown therapeutic
benefits in mouse models of inflammatory arthritis. Whether such agents have benefits in
human disease requires further work, with a recently concluded human trial of PPARγ
agonists in rheumatoid arthritis awaiting reporting (ClinicalTrials.gov; NCT00554853).
Transplantation
Prescription of immunosuppressive drugs to patients following transplantation is often
necessary to delay or prevent allograft rejection. However, such immunosuppressive
medications exhibit numerous side effects and may not be effective for long-term allograft
survival. Apoptotic cells carry self-antigens and actively dampen immunity and apoptotic
cell-based therapy has been developed to limit allograft rejection by promoting
immunological tolerance towards donor organs, tissues or cells130 (Box 3). Inoculation of
apoptotic cells from the donor in transplant recipients, prior to or during transfusion or
transplantation, seems to improve donor cell engraftment and solid allograft survival in a
variety of murine models131–134 (Figure 2). Depending on the experimental system, it was
shown that recipient DCs and/or macrophages are necessary to mediate the apoptotic cell-
induced tolerogenic effects on engraftment134,135. Masking the PtdSer on apoptotic cells
failed to provide the same benefit, suggesting that recognition and uptake of donor apoptotic
cells is necessary induce allograft tolerance132. Mechanistically, uptake of donor apoptotic
cells by splenic DCs was found to promote the generation/expansion of CD4+ FOXP3+
regulatory T cells and deletion of alloreactive CD4+ T cells, representing a potential
mechanism to reduce the risk of transplant rejection133. The potential use of apoptotic cell-
based therapy to induce immune tolerance towards certain antigens has implications beyond
transplantation, in particular the treatment of autoimmune diseases (Box 3).
Box 3
Apoptotic cells as a potential therapeutic intervention
Apoptotic cells or apoptotic cell mimics have immunomodulatory functions and their
administration could be used as a potential therapeutic intervention. Extracorporeal
photopheresis, where leukocytes are made apoptotic ex vivo prior to systemic re-
administration, is already an accepted treatment for cutaneous T cell lymphoma in
humans and has shown benefits in transplant rejection, graft-versus-host disease and
autoimmune disorders170.
Although the molecular events underlying the potential immune regulating function of
apoptotic cells are less clear, transforming growth factor-β (TGFβ)-dependent expansion
of regulatory T cells as well as changes in macrophage phenotype have been implicated
in apoptotic cell-mediated immune modulation134,171. Administration of cells made
apoptotic ex vivo has been shown to reduce both the acute and chronic phases of
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inflammatory arthritis in rodents172 by reducing the levels of tumour necrosis factor
(TNF) (which negatively regulates apoptotic cell clearance)173 and enhancing the
production of TGFβ and the generation of regulatory T cells172. Local administration of
apoptotic cells has also been used to attenuate both bleomycin- and lipopolysaccharide
(LPS)-induced lung inflammation, with reduced neutrophil recruitment into the lung,
enhanced phagocytosis by alveolar macrophages, reduced pro-inflammatory cytokine
production and increased TGFβ production after apoptotic cell delivery174,175. Infusion
of apoptotic cells 24 hour post initiation of sepsis has also been shown to protect against
lethality in a mouse model of sepsis with reduced pro-inflammatory cytokines and
neutrophil recruitment into organs176. At least part of the beneficial effect in the sepsis
model was mediated by the direct binding of LPS by apoptotic cells, which led to the
recognition and clearance of LPS-covered apoptotic cells by macrophages in an anti-
inflammatory manner176.
However the therapeutic use of apoptotic cells needs to be carefully considered in cases
where the capacity for apoptotic cell engulfment is reduced in vivo, as administered cells
may progress into secondary necrosis, which could exacerbate inflammation or
autoimmunity. Notably, macrophages that ingest necrotic cells cause increased T cell
proliferation177. Moreover, the repeated administration of apoptotic cells can lead to
autoimmunity178. Whether apoptotic cell mimics, such as PtdSer-containing liposomes,
can deliver the benefits of apoptotic cells without risking autoimmunity awaits further
investigation, but this strategy has already been used to improve skin oedema and post-
myocardial infarct repair in mice179,180. In addition, strategies that generate apoptotic
cells in situ in models of inflammation have shown potential: therapeutic agents with
cyclin-dependent kinase inhibitors181, flavones182 and the death receptor ligand
TRAIL183 have all demonstrated benefits in models of inflammation. Furthermore,
combined delivery of apoptotic cells with enhancers of phagocytosis may be required for
full therapeutic efficacy to prevent secondary necrosis of apoptotic cells.
Cancer
High levels of cell death can occur within a tumour milieu, and the mechanisms through
which dying tumour cells are cleared can profoundly influence tumour-specific immunity.
Thus, manipulation of the immunological context of dying cell removal has a great potential
for the control of tumour progression and generation of an anti-tumour response136. One
possible approach to promote anti-tumour immunity is by counteracting the
immunosuppressive properties of apoptotic cells. Supporting this notion, interfering with
PtdSer-mediated recognition of dying cells by masking PtdSer with annexin V favours an
anti-tumour response, possibly by delaying apoptotic cell clearance and bias the type of
phagocyte (for example DCs) that mediates cell clearance137. However, it is important to
note that blocking apoptotic cell engulfment may promote sterile inflammation through the
release and exposure of DAMPs by uncleared secondary necrotic cells (Box 1). Chronic
inflammation that results from this approach might conversely favour tumour growth138,139,
as well as autoimmunity115, and needs to be considered carefully.
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An alternative approach to promote anti-tumour immunity is by triggering an immunogenic
form of tumour cell death through specific cell death inducers. The ability of certain
chemotherapeutic drugs such as doxorubicin (an anthracycline) to augment anti-tumour
immunity via a caspase-, DC- and CD8+ T cell-dependent mechanism140, was found to
depend on the molecular machinery for dying cell clearance44,45. Anthracyclines seem to
promote exposure of the eat-me signal CRT on tumour cells, and blockade of CRT exposure
on anthracycline-treated tumour cells can markedly reduce DC-mediated cell clearance and
anti-tumour immunity44 (Figure 2). Importantly, supplying exogenous CRT to dying tumour
cells that cannot display endogenous CRT enhanced their phagocytosis by DCs and their
immunogenicity44. In addition to CRT, other DAMPs that are released by dying tumour
cells, such as HSP90 and HMGB1, can promote anti-tumour immunity through a DC-
dependent process141,142.
Cancer cells often hijack a variety of normal cellular processes to enable survival and
expansion in an organism. Recently, the ability of tumour cells to upregulate the don’t eat-
me signal CD47 to evade recognition and engulfment by phagocytes was found in many
mouse myeloid leukemias, as well as in patients with myeloid proliferative diseases
(including acute myeloid leukemia and myeloid blast crisis phase chronic myeloid
leukemia)143. Importantly, higher expression of CD47 in patients with acute myeloid
leukemia, non-Hodgkin lymphoma, ovarian cancer, glioma and glioblastoma correlated with
poor prognosis143–145, indicating a link between CD47 upregulation and tumorigenicity.
Consistent with the function of CD47 as a don’t eat-me signal through interaction with
macrophage SIRPα, ectopic expression of CD47 in a CD47low acute myeloid leukemia cell
line was reported to increase tumour cell survival by limiting their engulfment by
macrophages143. Importantly, CD47 blockade using a CD47-specific antibody in mice that
had received CD47high tumour cells from human patients reduced tumour engraftment,
growth and metastasis, thereby indicating therapeutic potential for CD47-targeting in
cancer144–147 (Figure 2). Recently, combination therapy using tumour-specific monoclonal
antibodies (for example rituximab and trastuzumab) and soluble SIRPα variants that can
antagonize CD47 function exhibit synergistic effect in promoting engulfment of tumour
cells by macrophages and regression of tumour growth in mouse models147.
Taken together, the evidence suggests that manipulation of the apoptotic cell clearance
process by delaying apoptotic cell recognition and removal, inducing immunogenic cell
death, and targeting cell clearance machinery hijacked by tumour cells, can effectively
promote anti-tumour immunity. However, challenges remain in validating these novel
therapeutic approaches clinically. Moreover, whether other aspects of the apoptotic cell
clearance process, such as phagocyte recruitment and formation of apoptotic bodies and
microparticles, can be modulated to control tumour progression warrants further
investigation.
Concluding remarks
It has been suggested that prompt and efficient clearance of apoptotic cells is the ultimate
goal of the apoptotic program, as well as a key process that can prevent inflammation and
maintain self-tolerance under physiological conditions. Accumulating evidence suggests that
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clearance of apoptotic cells is impaired in multiple human disease processes, with mounting
evidence indicating that the defect in apoptotic cell clearance is directly involved in driving
disease pathogenesis in several different contexts. Furthermore, over the past several years, a
number of exciting discoveries have been made on the molecules and mechanisms
regulating apoptotic cell clearance from model organisms to humans.
What is particularly revealing is that several steps within the process can be beneficial: the
molecules exposed on the apoptotic cells themselves appear to provide important
differentiation signals; the phagocytic recognition step induces several anti-inflammatory
mediators that dampen the immune response; the actual corpse internalization process
appears to help limit certain infections; depending on the type of apoptosis induction and the
type of phagocyte, the engulfment process can also be made pro-immunogenic in specific
conditions. This combined knowledge opens new avenues in therapeutic intervention for
both dampening inflammation in specific autoimmune or inflammatory disease states and
promoting effective immune responses against tumour-derived antigens. The next challenge
for the field is in harnessing the benefits of apoptotic cell clearance process for human
therapies.
Glossary
Professional and non-
professional
phagocytes
Professional phagocytes such as macrophages and immature
dendritic cells can efficiently detect and engulf pathogens and
dying cells. Non-professional phagocytes including fibroblasts,
epithelial cells, and endothelial cells can also engulf a variety of
particles including their dying brethren, but their primary
function is not phagocytosis
Plasma membrane
bleb
A globular protrusion seen at the plasma membrane. Membrane
blebs are dynamic and can occur during cell migration,
cytokinesis, and apoptosis
Apoptotic bodies Subcellular fragments released from apoptotic cells that are
approximately 1–5 μm in size. Apoptotic bodies are non-
uniform membrane-bound particles that contain portions of
cytoplasm and fragmented organelles
Focal adhesion A macromolecular complex that functions as a structural link
between the cell and the extracellular matrix. Components of
focal adhesion are also important for regulating intracellular
signalling
Adherens junction An inter-cellular macromolecular complex that mediates cell-
cell adhesion. Cadherin and catenin are key components of
adherens junction
Germinal centre A lymphoid structure that arises within follicles after
immunization with, or exposure to, a T-cell-dependent antigen.
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It is specialized for facilitating the development of high-
affinity, long-lived plasma cells and memory B cells
Apoptotic cell-derived
microparticles
Another category of subcellular fragments released from
apoptotic cells that are approximately 0.1–1 μm in size.
Apoptotic cell-derived microparticles and apoptotic bodies
represent a spectrum of membrane-bound apoptotic vesicles
characterized mainly by size and density
Aminophospholipid
asymmetry of the
plasma membrane
Distribution of aminophospholipids (such as PtdSer,
phosphatidylethanolamine and phosphatidylcholine) between
the outer and inner leaflet of the plasma membrane is often
asymmetrical, and may differ depending on the cell type,
activation status, and viability. This asymmetry is actively
maintained by ATP-dependent processes, and compromised by
activation of phospholipid scramblases
Endoplasmic
reticulum stress (ER
stress)
A response by the ER that results in the disruption of protein
folding and in the accumulation of unfolded proteins in the ER
Photodynamic
therapy
A treatment that uses a combination of a specific wavelength of
light and a photosensitizing agent to induce the production of
reactive oxygen species and cause lethal damage to the cells
Pathogen-associated
molecular patterns
(PAMPs)
Molecular signatures that are found in pathogens but not in
mammalian cells. Examples include terminally mannosylated
and polymannosylated compounds (which bind the mannose
receptor) and various microbial components, such as bacterial
lipopolysaccharide, hypomethylated DNA, flagellin and
double-stranded RNA (all of which bind Toll-like receptors)
Damage-associated
molecular patterns
(DAMPs)
As a result of cellular stress, cellular damage and non-
physiological cell death, DAMPs are released from the
degraded stroma (for example, hyaluronate), from nucleus (for
example, high-mobility group box 1 protein, HMGB1), from
the cytosol (for example, ATP, uric acid, S100 calcium-binding
proteins and heat-shock proteins) and from mitochondria
(formylated peptides and mitochondrial DNA). Such DAMPs
are thought to elicit both local and systemic inflammatory
reactions
Chronic obstructive
pulmonary disease
(COPD)
A group of diseases characterized by the pathological limitation
of airflow in the airway, including chronic obstructive
bronchitis and emphysema. Is most often caused by tobacco
smoking, but can also be caused by other airborne irritants, such
as coal dust, and occasionally by genetic abnormalities, such as
α1-antitrypsin deficiency
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Pulmonary fibrosis A heterogenous group of disorders characterised by diffuse
abnormalities of the pulmonary interstitium, with increased and
variable inflammation and fibrosis. Frequently of unknown
aetiology, pulmonary fibrosis can also be related to
autoimmune disease and secondary to medications
Cystic fibrosis An autosomal recessive genetic condition secondary to
mutations in the cystic fibrosis transmembrane conductance
regulator (CFTR; a chloride channel). This leads to a
multisystem disorder with lung, gastrointestinal, endocrine and
fertility complications. Chronic infection of the lungs ensues
leading to significant morbidity and mortality
Intima The innermost layer of an artery, which consists of loose
connective tissue and is covered by a monolayer if endothelium.
Atherosclerotic plaques form in the intima
C1q A complement protein and component of the classical
complement pathway. Involved in diverse functions including
immune function, autoimmunity and clearance of apoptotic
cells
Statins A family of inhibitors targeting hydroxymethylglutaryl-
coenzyme A reductase (HMG-CoA reductase), an enzyme that
catalyses the conversion of HMG-CoA to L-mevalonate. These
molecules are mainly used as cholesterol-lowering drugs, but
they also have immunoregulatory and anti-inflammatory
properties. L-Mevalonate and its metabolites are implicated in
cholesterol synthesis and other intracellular pathways
Foam cell A macrophage in the arterial wall that ingests oxidized low-
density lipoprotein and assumes a foamy appearance. These
cells secrete various substances contributing to plaque growth
Cross-presentation A process that describes the ability of antigen-presenting cells
to display a peptide fragment from exogenous antigen, via
MHC class I molecules, to CD8+ T cells
Organelle
fragmentation
A process during apoptosis that aids disassembly of organelles
into smaller portions. Organelle fragmentation is driven by
caspase-mediated cleavage of certain proteins and actomyosin
contraction
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Figure 1. Phases of apoptotic cell clearance
Cells undergoing apoptosis often exhibit morphological changes (for example membrane
blebbing and cellular shrinkage) to facilitate cell detachment and organelle fragmentation.
Prior to or during the onset of apoptotic morphology, apoptotic cells also release ‘find-me’
signals in the form of soluble factors (for example nucleotides) or microparticle-associated
molecules (including CX3C chemokine ligand 1 (CX3CL1) and intercellular adhesion
molecule 3 (ICAM3)) to recruit phagocytes for cell clearance. Nucleotides are released from
apoptotic cells via caspase-activated pannexin 1 (PANX1) membrane channels. Whether
detection of ‘find-me’ signals by phagocytes can prepare molecular machinery necessary for
engulfment in addition to cell migration warrants further investigation. Exposure of ‘eat-me’
signals (such as phosphatidylserine (PtdSer) and calreticulin (CRT)) accompanied by
modification of ‘don’t eat-me’ signals (CD31) on apoptotic cells or fragments of apoptotic
cell (also referred to as apoptotic bodies) mediate their recognition by phagocytes.
Phagocytes can engage ‘eat-me’ signals directly via cell surface receptors (such as brain-
specific angiogenesis inhibitor (BAI-1) and CD91) or indirectly through bridging molecules
(such as milk fat globule-EGF factor 8 (MFG-E8)) that are in turn detected by membrane
receptors (αVβ3). Subsequent downstream signalling initiates engulfment and engulfment-
associated responses from phagocytes. The mechanism underpinning the formation of
apoptotic bodies and microparticles is not fully defined. P2Y2, purinergic receptor P2Y2;
ROCK I, Rho-associated coiled-coil containing protein kinase I.
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Figure 2. Potential approaches for targeting the apoptotic cell clearance process for therapeutic
benefits
a. Bacterial infection. Following phagocytosis of invading bacteria, neutrophils frequently
undergo a form of ‘phagocytosis induced cell death’ (PICD) with subsequent engulfment by
surrounding phagocytes, providing a second round of pathogen destruction. The engulfing
phagocytes also increase production of pro-resolving lipid mediator release (for example
RvD1) with enhanced host-directed bacterial killing. b. Acute inflammation. Reactive
oxygen species (ROS) that are produced at sites of acute inflammation impair phagocytosis
through the activation of RhoA within phagocytes. Scavenging ROS (for example by using
N-acetylcystein; NAC) enhances apoptotic cell clearance. c. Glucocorticoids can potentially
augment eosinophil clearance by promoting both eosinophil apoptosis and cell clearance via
a protein S–Mer-dependent pathway. d. Atherosclerosis. Impaired engulfment in
atherosclerosis is, in part, mediated by increased activity of RhoA and its downstream
mediator ROCK, both of which are negative regulators of apoptotic cell engulfment. RhoA
inhibition by HMG-CoA reductase inhibitors (statins) or ROCK inhibition seems to have a
beneficial effect in atherosclerosis, possibly by regulating engulfment. e. Rheumatoid
arthritis. At sites of inflammation, extracellular damage-associated molecular patterns
(DAMPs) such as histones and HMGB1 negatively regulate apoptotic cell engulfment by
binding to integrins on the surface of phagocytes. Strategies to degrade DAMPs (for
example through the degradation of histone H3 by antigen presenting cells (APCs)) can
improve apoptotic cell clearance. f. Recognition and uptake of donor apoptotic cells by
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recipient DCs and macrophages can promote donor-specific tolerance in the recipients and
limit allograft rejection. g. Induction of tumour cell death accompanied with CRT and
DAMPs exposure can promote DC-mediated engulfment and DC maturation to initiate an
anti-tumour immune response. h. Targeting tumour cells with anti-CD47 blocking
antibodies or soluble SIRPα variants inhibits CD47-SIRPα interaction and facilitates tumour
cell removal by macrophages.
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Table 1
Molecular machinery of apoptotic cell recognition
SIGNAL RELEASE/EXPOSURE MECHANISM RECOGNITION MECHANISM DETAILS/COMMENTS REFERENCE
‘Find-me’
Nucleotides PANX1 P2Y2 Release of ATP/UTP
from apoptotic cells
promotes monocyte and
macrophage migration in
vitro and in vivo. Other
P2Y family members may
also facilitate detection of
nucleotides by
phagocytes.
15,16
LPC ? G2A Caspase 3-mediated
activation of iPLA2 is also
necessary to generate LPC
during apoptosis. LPC
augments monocyte
migration in vitro.
18
SIP ? ? Purified SIP enhances
monocyte and
macrophage migration in
vitro.
19
ICAM-3 Microparticles ? ICAM-3 localizes to
apoptotic blebs and
microparticles during
apoptosis. ICAM-3 may
also facilitate tethering of
apoptotic B cells to
macrophages.
21,184
CX3CL1 Microparticles CX3CR1 CX3CL1/CX3CR1
participates in the
recruitment of
macrophages to lymphoid
follicles undergoing
germinal center reactions.
22
EMAP II ? ? Generation and release of
mature EMAP II occurs
during apoptosis. The
ability of apoptotic cell-
derived EMAP II to
promote phagocyte
migration has not been
examined directly.
185
Annexin A1 Membrane lysis ? Release and proteolytic
processing of annexin A1
by ADAM10 during
secondary necrosis
promotes migration of
monocytes. Annexin A1
may also participate in the
engulfment step of
apoptotic cell clearance.
186,187
‘Keep-out’
Lactoferrin ? ? Release from apoptotic
cells to inhibit neutrophil
migration.
23
‘Eat-me’
PtdSer Phospholipid scramblase/amino-phospholipid translocase? BAI1 BAI1 functions upstream
of the ELMO1-Dock180-
Rac module to mediate
apoptotic cell recognition
30
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SIGNAL RELEASE/EXPOSURE MECHANISM RECOGNITION MECHANISM DETAILS/COMMENTS REFERENCE
and engulfment. BAI1
interacts with PtdSer
though its
thrombospondin type 1
repeats.
TIM1/3/4 Metal-ion-dependent
ligand binding site located
in the IgV domain of
TIM-4 mediates PtdSer
binding. TIM-3 may also
play an important role in
regulating cross-
presentation of apoptotic
cell-associated antigens
by CD8+DCs.
33–35
Stabilin-2 Stabilin-2 functions
upstream of GULP and
thymosin β4 to aid
apoptotic cell clearance.
Stabilin-2 binds PtdSer
via its epidermal growth
factor-like domain
repeats.
31,32,36,37
MFG-E8 – αVβ3 MFG-E8 is secreted by
‘activated’ macrophage
and immature DCs to
promote apoptotic cell
engulfment. MFG-E8
interacts with PtdSer and
αVβ3 via its factor-VIII-
homologous domains and
RGD motif, respectively.
40
Protein S/Gas6 – Tryo-3/Axl/Mer Protein S and Gas6
interact with PtdSer and
TAM receptors via their
Gla domains and sex
hormone binding globulin
domains, respectively.
Usage of different TAM
receptors is dependent on
phagocyte and organ type.
39,41,188,189
RAGE RAGE is thought to
function upstream of Rac1
to aid apoptotic cell
recognition and uptake by
alveolar macrophages.
190
CRT Exocytic? CD91 Conditions that can
induce both apoptosis and
ER stress can facilitate
pre-apoptotic exposure of
CRT.
42,44,191
‘Don’t eat-me’
CD31 N/A CD31 Homophilic interaction of
CD31 on leukocytes and
macrophages promotes
cell detachment. How
signalling-disabled CD31
are generated on apoptotic
leukocytes is unknown.
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SIGNAL RELEASE/EXPOSURE MECHANISM RECOGNITION MECHANISM DETAILS/COMMENTS REFERENCE
CD47 N/A SIRP α Besides functioning as a
‘don’t eat-me signal’,
evidence also suggest that
CD47 on apoptotic
lymphocytes could aid
apoptotic cell binding to
macrophages.
42,193
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